Skip to main content
Fig. 4 | Cancer Nanotechnology

Fig. 4

From: Retro-inversion follicle-stimulating hormone peptide-modified nanoparticles for delivery of PDK2 shRNA against chemoresistant ovarian cancer by switching glycolysis to oxidative phosphorylation

Fig. 4

PDK2 knockdown induced a switch from glycolysis to OXPHOS. A The ECAR measured by Seahorse analysis in cisplatin-resistant A2780cp ovarian cancer cells. Cells were transfected with PDK2 shRNA and then treated with 5 μg/ml cisplatin for 24 h. Quantification of non-glycolytic acid production (B), glycolysis (C) and glycolytic capacity (D). E The OCR measured by Seahorse analysis in A2780cp cells. Quantification of basal respiration (F), ATP production (G) and maximum respiration (H). I Lactate level in supernatants. J PDHC activity in A2780cp cells. A2780cp cells were transfected with PDK2 shRNA (PDK2shRNA group) or scramble shRNA (control group) for 24 h. Then, both PDK2-depleted A2780cp cells and control cells were treated with 5 μg/ml cisplatin for 24 h (cis + PDK2shRNA group vs. cisplatin group). K The levels of electron transport chain complexes in the PDK2-depleted A2780cp cells detected via Western blot. ***P < 0.001, **P < 0.01, and *P < 0.05

Back to article page